Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE
Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE
复制标题
DOI：
10.1006/cyto.2001.0934
复制
发表时间：
2001-09-07
期刊：
影响因子：
3.8
通讯作者：
Stewart, TA
中科院分区：
文献类型：
--
作者：
Chuntharapai, A;Lai, J;Stewart, TA
我们已经开发了一组识别人干扰素α的鼠单克隆抗体。这些单克隆抗体之一以高亲和力结合并中和所有七种测试的重组人干扰素α。该单克隆抗体还中和在刺激人外周血白细胞后制备的两个独立的α干扰素池中存在的干扰素活性。将该鼠单克隆抗体的互补决定区转移至人IgG 2重链和人κ 1轻链。此外，从框架区转移了6个（重链）和2个（轻链）氨基酸。这产生了保留小鼠亲本特异性的人源化单克隆抗体。人源化抗干扰素α抗体是那些疾病的候选治疗剂，例如胰岛素依赖性糖尿病、系统性红斑狼疮、银屑病和克罗恩病，这些疾病的特征都是干扰素α的病理表达。(C)北京：科学出版社.
We have developed a panel of murine monoclonal antibodies that recognize human interferon alpha. One of these mononclonal antibodies binds and neutralizes, with high affinity, all of seven tested recombinant human interferon alphas. This mononclonal antibody also neutralizes the interferon activity present in two independent pools of interferon alphas prepared following stimulation of human peripheral blood leukocytes. The complementary determining regions from this murine mononclonal antibody were transferred to a human IgG2 heavy chain and to a human kappa1 light chain. In addition, six (heavy chain) and two (light chain) amino acids were transferred from the framework regions. This generated a humanized mononclonal antibody that retained the specificity of the mouse parent. The humanized anti-interferon alpha antibody is a candidate therapeutic for those diseases, such as insulin-dependent diabetes, systemic lupus erythematosis, psoriasis and Crohn's disease, which are all characterized by pathological expression of interferon alpha. (C) 2001 Academic Press.